Better Therapeutics- Tradeable Rights - March 2021 EBIT

As of the most recent data (September 2023), MCADR shows a EBIT of $-32M. That compares with $-42M in the prior-year period — up 24.1% year over year. That is below the sector sector average of $2.6T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MCADR's EBIT is now $-32M (was $-42M) — a 24.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Better Therapeutics- Tradeable Rights - March 2021 is outperforming or lagging.

The its sector sector average EBIT is about $2.6T. Better Therapeutics- Tradeable Rights - March 2021 is at $-32M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how MCADR stacks up against individual peers as well.

Tracking MCADR's ebit over time shows whether Better Therapeutics- Tradeable Rights - March 2021 is scaling, shrinking, or reshaping that part of the business. The current reading is $-32M That compares with $-42M in the prior-year period — up 24.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Better Therapeutics- Tradeable Rights - March 2021's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-32M) with ownership activity and broader fundamentals.